This year, the United States is expected to spend nearly $15 billion on healthcare for HIV patients, which still doesn’t cover all of the patients who need treatment. But those costs are expected to decrease in the next few years as the patents for brand-name antiretrovirals expire.

“AIDS, as we currently know it, may become much more affordable,” John Bartlett, an infectious-disease researcher at Johns Hopkins Bloomberg School of Public Health, told Nature.

The three-in-one antiretroviral Atripla is considered the go-to first line therapy for HIV and is made up of two drugs made by Gilead Sciences and one by Bristol-Myers Squibb (BMS). While only one component from this cocktail, BMS’s efavirenz, will go off patent next year, a second component already has a readily available generic substitute. The cost saving from these two drugs is estimated to save $920 million in the first year.

Although it will be...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?